Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Sep. 2013,
ViroPharma, received€3.8 Mil more from issuing new shares than it paid to buy back shares.
It received€0.0 Mil from issuing more debt.
It paid€0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.0 Mil from paying cash dividends to shareholders.
It received€1.2 Mil on other financial activities.
In all, ViroPharma,earned€5.0 Mil on financial activities for the
three
months ended in Sep. 2013.
ViroPharma, Cash Flow from Financing Historical Data
The historical data trend for ViroPharma,'s Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
ViroPharma,'s Cash from Financing for the fiscal year that ended in Dec. 2012 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroPharma, (FRA:VPH) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
ViroPharma,'s issuance of stock for the
three
months ended in Sep. 2013 was €3.8 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
ViroPharma,'s repurchase of stock for the
three
months ended in Sep. 2013 was €0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
ViroPharma,'s net issuance of debt for the
three
months ended in Sep. 2013 was €0.0 Mil.
ViroPharma, received€0.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
ViroPharma,'s net issuance of preferred for the
three
months ended in Sep. 2013 was €0.0 Mil.
ViroPharma, paid€0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
ViroPharma,'s cash flow for dividends for the
three
months ended in Sep. 2013 was €0.0 Mil.
ViroPharma, received€0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
ViroPharma,'s other financing for the
three
months ended in Sep. 2013 was €1.2 Mil.
ViroPharma, received€1.2 Mil on other financial activities.
ViroPharma, Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of ViroPharma,'s Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:VPH has been successfully added to your 